journal
https://read.qxmd.com/read/38704319/development-and-validation-of-a-multicenter-cox-regression-model-to-predict-all-cause-mortality-in-patients-with-renal-masses-suspicious-for-renal-cancer
#1
JOURNAL ARTICLE
Brian R Lane, Joseph G Cheaib, Dennis Boynton, Phillip Pierorazio, Sabrina L Noyes, Henry Peabody, Nirmish Singla, Anna Johnson, Khurshid R Ghani, Andrew Krumm, Karandeep Singh
OBJECTIVE: Life expectancy models are useful tools to support clinical decision-making. Prior models have not been used widely in clinical practice for patients with renal masses. We sought to develop and validate a model to predict life expectancy following the detection of a localized renal mass suspicious for renal cell carcinoma. MATERIALS AND METHODS: Using retrospective data from 2 large centers, we identified patients diagnosed with clinically localized renal parenchymal masses from 1998 to 2018...
May 3, 2024: Urologic Oncology
https://read.qxmd.com/read/38702232/contemporary-morbidity-and-mortality-of-open-versus-robotic-cystectomy-for-bladder-cancer-an-analysis-of-the-national-surgical-quality-improvement-program-nsqip-procedure-targeted-cystectomy-database
#2
JOURNAL ARTICLE
Zachary Melchiode, Siqi Hu, Jiaqiong Xu, Carlos Riveros, Sameer Farooq, Sanjana Ranganathan, Emily Huang, Brian J Miles, Dharam Kaushik, Christopher J D Wallis, Raj Satkunasivam
OBJECTIVES: To evaluate the association between surgical modality (RARC vs. ORC) and the risk of 30-day complications. MATERIALS AND METHODS: We utilized the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) Cystectomy-Targeted database from 2019 to 2021. The primary outcome was a composite of major complications including 30-day mortality, reoperation, cardiac events, and stroke. Secondary outcomes included individual major and cystectomy-specific complications...
May 2, 2024: Urologic Oncology
https://read.qxmd.com/read/38697874/pathologic-and-survival-outcomes-following-radical-cystectomy-for-progressive-and-de-novo-muscle-invasive-bladder-cancer-a-meta-analysis-stratified-by-neoadjuvant-chemotherapy-status
#3
JOURNAL ARTICLE
Leilei Xia, Anosh Dadabhoy, Erika L Wood, Sejal V Mehta, Daniel S Roberson, Thomas J Guzzo, Trinity J Bivalacqua, Siamak Daneshmand
OBJECTIVE: To compare survival and pathologic outcomes in patients with progressive muscle-invasive bladder cancer (pgMIBC) and de novo muscle-invasive bladder cancer (dnMIBC) after radical cystectomy (RC), with a focus on the role of neoadjuvant chemotherapy (NAC). METHODS: A comprehensive literature search was conducted on PubMed and EMBASE databases to identify studies comparing pgMIBC to dnMIBC. Survival outcomes, including cancer-specific survival (CSS), overall survival (OS), and recurrence-free survival (RFS), and pathologic outcomes (rates of ≤pT1, pT0, pT3/T4, and pN+ disease) were compared between pgMIBC and dnMIBC...
May 1, 2024: Urologic Oncology
https://read.qxmd.com/read/38688797/incidence-and-management-of-prostatic-urethra-recurrence-in-a-cohort-of-21-patients-who-received-bcg-induction-for-non-muscle-invasive-bladder-cancer
#4
JOURNAL ARTICLE
Justin W Ingram, Rainjade Chung, Caroline Laplaca, James M McKiernan, Andrew T Lenis, Christopher B Anderson
PURPOSE: To describe the incidence and management of patients who develop a prostatic urethral (PU) urothelial carcinoma recurrence after Bacillus Calmette-Guerin (BCG) induction for non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We performed a retrospective cohort study of all patients who received BCG induction at our institution from 1996 to 2021 (N = 642) for NMIBC. All patients with pathologically confirmed PU involvement following BCG induction with no known PU involvement pre-BCG were included...
April 29, 2024: Urologic Oncology
https://read.qxmd.com/read/38679529/cost-of-upper-tract-imaging-obtained-during-hematuria-evaluation-analysis-of-a-national-claims-database
#5
JOURNAL ARTICLE
Alex Hannemann, Rodrigo Rodrigues Pessoa, Thomas Flaig, Elizabeth Molina Kuna, Adam Warren, Tyler Robin, Simon P Kim, Eric Ballon-Landa
INTRODUCTION: To investigate the actual cost of hematuria evaluation using nationally representative claims data, given that the workup for hematuria burdens the healthcare system with significant associated costs. We hypothesized that evaluation with contrast-enhanced computed tomography (CT) confers more cost to hematuria evaluation than renal ultrasound (US). METHODS: Using a national, privately insured database (MarketScan), we identified all individuals with an incident diagnosis of hematuria...
April 27, 2024: Urologic Oncology
https://read.qxmd.com/read/38677938/the-emotional-toll-of-surgical-complications-in-the-early-career
#6
REVIEW
Amy N Luckenbaugh
Surgical complications and errors impact all surgeons throughout their career. Early career surgeons may be particularly vulnerable. In this invited manuscript the impact of surgical complications on early career surgeons is discussed. Review of current systems to aid in emotional support of complications is provided.
April 26, 2024: Urologic Oncology
https://read.qxmd.com/read/38670817/histologic-and-molecular-landscape-of-genitourinary-tumors-and-clinical-implications
#7
EDITORIAL
Deepika Sirohi
No abstract text is available yet for this article.
April 26, 2024: Urologic Oncology
https://read.qxmd.com/read/38670818/efficacy-of-conduction-hyperthermia-in-the-treatment-of-non-muscle-invasive-bladder-cancer-a-systematic-review
#8
REVIEW
M Teresa Melgarejo Segura, Yaiza Yáñez Castillo, Macarena Lozano Lorca, Ana Morales Martínez, Miguel Ángel Arrabal Polo, Miguel Arrabal Martín
INTRODUCTION: Intravesical treatment for non-muscle invasive bladder cancer (NMIBC) aims to reduce recurrences and stop progression. Hyperthermia-enhanced chemotherapy with devices like COMBAT BRS, Unithermia, and BR-TRG-I is a promising alternative to conventional Bacillus de Calmette Guerin (BCG) therapy. OBJECTIVE: To systematically review the efficacy of hyperthermia generated by conduction devices in the treatment of NMIBC. MATERIAL AND METHODS: The review followed the preferred reporting items for systematic reviews and meta-analyses guidelines...
April 25, 2024: Urologic Oncology
https://read.qxmd.com/read/38670816/patient-and-caregiver-related-factors-affecting-family-caregiver-burden-of-urologic-cancer-patients
#9
JOURNAL ARTICLE
Li Ping Wong, Xiaonan Xu, Haridah Alias, Chuo Yew Ting, Hui Meng Tan, Yulan Lin
OBJECTIVE: This study aimed to investigate the level of family caregivers' (FC) burden and the extent to which patient- and caregiver-related factors influence the caregiving burden among FCs of urologic cancer (UC) patients. METHOD: A cross-sectional survey was conducted on caregivers of UC patients who sought cancer care. The modified caregiver strain index (MCSI) was used to assess FC burden. RESULTS: Just over half (54.3%) of FCs had moderate/high MCSI scores (score 9-26)...
April 25, 2024: Urologic Oncology
https://read.qxmd.com/read/38664180/an-exploratory-study-investigating-the-impact-of-the-bladder-tumor-microbiome-on-bacillus-calmette-guerin-bcg-response-in-non-muscle-invasive-bladder-cancer
#10
JOURNAL ARTICLE
Jacob Knorr, Zaeem Lone, Glenn Werneburg, Ava Adler, Jose Agudelo, Mangesh Suryavanshi, Rebecca A Campbell, Kyle Ericson, Hong Qiu, Petar Bajic, Georges-Pascal Haber, Christopher J Weight, Philip P Ahern, Nima Almassi, Aaron W Miller, Byron H Lee
PURPOSE: Intravesical Bacillus Calmette-Guerin (BCG) is standard of care for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC). The effect of the bladder microbiome on response to BCG is unclear. We sought to characterize the microbiome of bladder tumors in BCG-responders and non-responders and identify potential mechanisms that drive treatment response. MATERIALS AND METHODS: Patients with archival pre-treatment biopsy samples (2012-2018) were identified retrospectively...
April 24, 2024: Urologic Oncology
https://read.qxmd.com/read/38664179/voided-urine-cytology-is-a-useful-tool-predicting-non-muscle-invasive-bladder-cancer-risk-before-surgery
#11
JOURNAL ARTICLE
Carmen Gómez Del Cañizo, Ignacio González Ginel, Cristina Martín-Arriscado Arroba, Ana de la Calle Moreno, Mario Hernández Arroyo, Alfredo Rodríguez Antolín, Félix Guerrero Ramos
OBJECTIVE: To determine the accuracy of voided urinary cytology (VUC) in predicting of non-muscle-invasive bladder cancer (NMIBC) risk stratification before surgery. METHODS: We prospectively collected data from all patients diagnosed with bladder cancer in our institution over 2 years. We have analyzed VUC accuracy of positive and suspicious VUC in the detection of high-risk tumors and negative and atypical VUC in the detection of low-risk tumors. To test this accuracy, we assessed sensitivity, specificity, positive (PPV) and negative predictive values (NPV), diagnostic odds ratio (DOR), and generated ROC curves (receiver operating characteristic curve)...
April 24, 2024: Urologic Oncology
https://read.qxmd.com/read/38653593/network-analysis-of-histopathological-image-features-and-genomics-data-improving-prognosis-performance-in-clear-cell-renal-cell-carcinoma
#12
JOURNAL ARTICLE
Jianrui Ji, Yunsong Liu, Yongxing Bao, Yu Men, Zhouguang Hui
INTRODUCTION: Clear cell renal cell carcinoma is the most common type of kidney cancer, but the prediction of prognosis remains a challenge. METHODS: We collected whole-slide histopathological images, corresponding clinical and genetic information from the The Cancer Imaging Archive and The Cancer Genome Atlas databases and randomly divided patients into training (n = 197) and validation (n = 84) cohorts. After feature extraction by CellProfiler, we used 2 different machine learning techniques (Least Absolute Shrinkage and Selector Operation-regularized Cox and Support Vector Machine-Recursive Feature Elimination) and weighted gene co-expression network analysis to select prognosis-related image features and genes, respectively...
April 22, 2024: Urologic Oncology
https://read.qxmd.com/read/38653592/hivec-as-an-alternative-option-in-non-muscle-invasive-bladder-cancer-experiences-from-a-high-volume-center
#13
JOURNAL ARTICLE
Lucas Kastner, Constantin Rieger, David Pfister, Max Schmautz, Enno Storz, Axel Heidenreich
BACKGROUND: High risk non-muscle invasive bladder cancer (NMIBC) is usually treated with intravesical BCG-therapy. In case of BCG failure radical cystectomy (RC) is the treatment of choice. Nevertheless, many patients are unfit for or unwilling to undergo RC. Hyperthermic intravesical chemotherapy (HIVEC) is a promising bladder sparing therapy in such cases. It was the purpose of the study to evaluate the efficacy of HIVEC in patients with BCG failure as well as in BCG naïve patients in case of BCG shortage or given contra-indications for BCG...
April 22, 2024: Urologic Oncology
https://read.qxmd.com/read/38653591/prognostic-significance-of-lymph-node-count-in-surgically-treated-patients-with-t-2-4-stage-nonmetastatic-adrenocortical-carcinoma
#14
JOURNAL ARTICLE
Anis Assad, Francesco Barletta, Reha-Baris Incesu, Lukas Scheipner, Simone Morra, Andrea Baudo, Cristina Cano Garcia, Zhe Tian, Sascha Ahyai, Nicola Longo, Felix K H Chun, Shahrokh F Shariat, Derya Tilki, Alberto Briganti, Fred Saad, Pierre I Karakiewicz
PURPOSE: The role of lymphadenectomy and the optimal lymph node count (LNC) cut-off in nonmetastatic adrenocortical carcinoma (nmACC) are unclear. METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database, surgically treated nmACC patients with T2-4 stages were identified between 2004 and 2020. We tested for cancer-specific mortality (CSM) differences according to pathological N-stage (pN0 vs. pN1) and two previously recommended LNC cut-offs (≥4 vs...
April 22, 2024: Urologic Oncology
https://read.qxmd.com/read/38653590/impact-of-body-composition-on-outcomes-of-immune-checkpoint-inhibitor-combination-therapy-in-patients-with-previously-untreated-advanced-renal-cell-carcinoma
#15
JOURNAL ARTICLE
Hiroki Ishihara, Koichi Nishimura, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi
BACKGROUND: Data on the association between body composition and outcomes in patients with advanced renal cell carcinoma (RCC) treated with immune checkpoint inhibitor (ICI) combination therapy are limited. METHODS: We retrospectively evaluated the clinical and radiographic data of 159 patients with advanced RCC, including 84 receiving ICI dual combination therapy (immunotherapy [IO]-IO group) and 75 receiving combinations of ICIs with tyrosine kinase inhibitors (TKIs) (IO-TKI group)...
April 22, 2024: Urologic Oncology
https://read.qxmd.com/read/38644109/preoperative-risk-calculator-for-the-probability-of-completing-nephron-sparing-for-kidney-cancer
#16
JOURNAL ARTICLE
Francesco Cei, Alessandro Larcher, Giuseppe Rosiello, Giuseppe Basile, Giacomo Musso, Chiara Re, Giuseppe Fallara, Federico Belladelli, Giorgio Brembilla, Giorgia Guazzarotti, Francesco De Cobelli, Laura Marandino, Andrea Necchi, Alberto Briganti, Andrea Salonia, Roberto Bertini, Francesco Montorsi, Umberto Capitanio
PURPOSE: In absence of predictive models, preoperative estimation of the probability of completing partial (PN) relative to radical nephrectomy (RN) is invariably inaccurate and subjective. We aimed to develop an evidence-based model to assess objectively the probability of PN completion based on patients' characteristics, tumor's complexity, urologist expertise and surgical approach. DESIGN, SETTING AND PARTICIPANTS: 675 patients treated with PN or RN for cT1-2 cN0 cM0 renal mass by seven surgeons at one single experienced centre from 2000 to 2019...
April 21, 2024: Urologic Oncology
https://read.qxmd.com/read/38643022/avoiding-needless-nephrectomy-what-is-the-role-of-small-renal-mass-biopsy-in-2024
#17
REVIEW
Bruce Gao, Antonio R H Gorgen, Rohit Bhatt, Zachary E Tano, Kalon L Morgan, Kelvin Vo, Sina Soltanzadeh Zarandi, Sohrab N Ali, Pengbo Jiang, Roshan M Patel, Ralph V Clayman, Jaime Landman
Current guidelines do not mandate routine preoperative renal mass biopsy (RMB) for small renal masses (SRMs), which results in a considerable rate (18%-26%) of needless nephrectomy/partial nephrectomy for benign renal tumors. In light of this ongoing practice, a narrative review was conducted to examine the role of routine RMB for SRM. First, arguments justifying the current non-biopsy approach to SRM are critically reviewed and contested. Second, as a standalone procedure, RMB is critically assessed; RMB was found to have higher sensitivity, specificity, and an equal or lower complication rate when compared with other commonly preoperatively biopsied solid organ tumors (e...
April 19, 2024: Urologic Oncology
https://read.qxmd.com/read/38641474/natural-history-and-health-care-burden-of-non-curative-treatment-for-muscle-invasive-bladder-cancer
#18
JOURNAL ARTICLE
Haim Herzberg, Yossi Ventura, Karin Lifshitz, Ziv Savin, Shay Golan, Jack Baniel, Ofer Yossepowitch, Roy Mano
OBJECTIVE: Muscle-invasive bladder cancer is an aggressive disease. Yet, many patients, especially those with advanced age and multiple comorbidities, do not receive treatment with curative intent. We evaluated the disease course and health care burden of these patients. MATERIALS AND METHODS: Bi-center, retrospective analysis of patients diagnosed with muscle-invasive bladder cancer who did not undergo curative-intent treatment (radical cystectomy or trimodal therapy) between 2016 and 2021...
April 18, 2024: Urologic Oncology
https://read.qxmd.com/read/38631967/open-versus-minimally-invasive-nephroureterectomy-in-octogenarians-an-analysis-of-surgical-approach-trends-outcomes-and-survival-analysis-with-propensity-matching
#19
JOURNAL ARTICLE
Shaun Trecarten, Mukund Bhandari, Ahmad Abdelaziz, Onika Noel, Michael Liss, Furkan Dursun, Robert Svatek, Ahmed M Mansour
INTRODUCTION: Upper tract urothelial carcinoma (UTUC) is a rare disease accounting only for 5%-10% of urothelial carcinoma (UC). For localized high-risk disease, radical nephroureterectomy (RNU) is the standard of care. While minimally invasive (MIS) RNU has not been shown to decisively improve overall survival (OS) compared to open surgery, MIS RNU has been associated with reduced hospital length of stay (LOS), blood transfusion requirements and improved recovery, which are important considerations when treating older patients...
April 16, 2024: Urologic Oncology
https://read.qxmd.com/read/38627107/estimation-of-the-incidence-of-urachal-cancer-a-systematic-review-and-meta-analysis-of-registry-based-studies
#20
JOURNAL ARTICLE
Csilla Olah, András Kubik, Péter Mátrai, Marie Anne Engh, Viktória Barna, Péter Hegyi, Henning Reis, Péter Nyirády, Tibor Szarvas
BACKGROUND: Urachal cancer (UrC) is a rare disease with limited availability of representative incidence and clinical data. Although, the prevalence is accounting for less than 1% of bladder tumors, the 5-year survival rate is around only 50% for patients with resectable tumors, and even worse for patients with metastatic disease. Due to the lack of comprehensive prospective studies, our current knowledge of UrC is still limited. OBJECTIVE: The present study aimed to summarize the available registry-based studies with unselected UrC patients to evaluate its incidence and clinicopathological characteristics...
April 15, 2024: Urologic Oncology
journal
journal
32958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.